Screener
Nektar Therapeutics NKTR Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| -$40.62M+2.3% | -$44.9M+11.7% | -$36.08M— | -$35.52M+4.1% | -$41.59M+20.6% | ||
| $156K-27.1% | $151K-64.6% | $190K-42.8% | $196K-80.3% | $214K-85.3% | ||
| $1.78M+47.7% | $3.36M-13.9% | $2.19M-54.3% | $3.07M-43.0% | $1.2M-77.8% | ||
| -$75.77M-65.7% | -$44.3M+9.7% | -$64.96M-40.6% | -$48.76M-11.0% | -$45.74M-21.3% | ||
| $94K+154% | $18K+800% | $18K-96.1% | $114K-82.9% | $37K-80.1% | ||
| -$399.11M-904% | -$350.79M-903% | —— | -$94.87M-306% | $49.62M+192% | ||
| $364.57M+172,682% | $529.55M+7,564,886% | $38.67M+46,492% | $141.68M+1,089,723% | $211K+1,011% | ||
| —— | $134.46M+2,610% | -$25.92M-283% | -$1.96M-190% | —— | ||
| -$75.86M-65.7% | -$44.32M+9.7% | -$64.98M-39.3% | -$48.88M-9.6% | -$45.78M-20.8% |
FAQ
- How much cash does Nektar Therapeutics generate?
- Nektar Therapeutics (NKTR) generated -$233.8M in operating cash flow over the trailing twelve months.
- What is Nektar Therapeutics's free cash flow?
- After $244.0K of capital expenditures, Nektar Therapeutics's free cash flow was -$234.0M over the trailing twelve months, down 25.8% year over year.
- Where does Nektar Therapeutics's cash flow data come from?
- Every line is extracted from Nektar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
